KR20210054544A - 포유류 체내의 myc-발현 종양에 대한 타우로리딘 치료 - Google Patents

포유류 체내의 myc-발현 종양에 대한 타우로리딘 치료 Download PDF

Info

Publication number
KR20210054544A
KR20210054544A KR1020217009412A KR20217009412A KR20210054544A KR 20210054544 A KR20210054544 A KR 20210054544A KR 1020217009412 A KR1020217009412 A KR 1020217009412A KR 20217009412 A KR20217009412 A KR 20217009412A KR 20210054544 A KR20210054544 A KR 20210054544A
Authority
KR
South Korea
Prior art keywords
composition
taurinamide
taurultam
dosage range
individual patient
Prior art date
Application number
KR1020217009412A
Other languages
English (en)
Korean (ko)
Inventor
브루스 레이덴버그
로버트 디루치오
Original Assignee
코르메딕스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코르메딕스, 인코포레이티드 filed Critical 코르메딕스, 인코포레이티드
Publication of KR20210054544A publication Critical patent/KR20210054544A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217009412A 2018-08-31 2019-09-03 포유류 체내의 myc-발현 종양에 대한 타우로리딘 치료 KR20210054544A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862725650P 2018-08-31 2018-08-31
US62/725,650 2018-08-31
PCT/US2019/049266 WO2020047530A1 (en) 2018-08-31 2019-09-03 Taurolidine treatment for myc-expressing tumors in mammalian bodies

Publications (1)

Publication Number Publication Date
KR20210054544A true KR20210054544A (ko) 2021-05-13

Family

ID=69643283

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217009412A KR20210054544A (ko) 2018-08-31 2019-09-03 포유류 체내의 myc-발현 종양에 대한 타우로리딘 치료

Country Status (7)

Country Link
EP (1) EP3843747A4 (zh)
JP (1) JP2021535167A (zh)
KR (1) KR20210054544A (zh)
CN (1) CN113226325A (zh)
AU (1) AU2019331913A1 (zh)
CA (1) CA3111100A1 (zh)
WO (1) WO2020047530A1 (zh)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9005856D0 (en) * 1990-03-15 1990-05-09 Geistlich Soehne Ag Compositions
US7151099B2 (en) * 1998-07-31 2006-12-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases
DE60030770T2 (de) * 1999-12-06 2007-09-06 Rhode Island Hospital Verwendung von taurolidin oder taurultam zur herstellung eines medikaments zur behandlung von ovarialkarzinomen
CN100519525C (zh) * 1999-12-06 2009-07-29 葛兰素集团有限公司 芳香砜类及其医疗用途
US20080171738A1 (en) * 2001-04-03 2008-07-17 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of Breast Cancer
CA2482687C (en) * 2003-09-29 2012-11-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
WO2007020509A1 (en) * 2005-08-15 2007-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth
US7928102B2 (en) * 2006-01-06 2011-04-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Irradiated compositions and treatment of cancers with radiation in combination with taurolidine and/or taurultam
ES2614878T3 (es) * 2010-06-01 2017-06-02 Geistlich Pharma Ag Métodos y composiciones para terapia farmacéutica oral
EP3402527B1 (en) * 2016-01-11 2022-09-28 CorMedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
ES2945712T3 (es) * 2016-03-18 2023-07-06 Geistlich Pharma Ag Método de tratamiento de cáncer de mama triple negativo

Also Published As

Publication number Publication date
CA3111100A1 (en) 2020-03-05
CN113226325A (zh) 2021-08-06
EP3843747A4 (en) 2022-12-28
EP3843747A1 (en) 2021-07-07
AU2019331913A1 (en) 2021-04-29
WO2020047530A1 (en) 2020-03-05
JP2021535167A (ja) 2021-12-16

Similar Documents

Publication Publication Date Title
JP2015078247A (ja) 放射線療法と併用して肺癌の治療に有用なラパマイシン含有高分子ナノ粒子静脈注射用抗癌組成物
IL269969B2 (en) 2-pmpa protrope for healthy tissue protection during imaging or radiotherapy of psma-targeted cancer
CN111587115A (zh) 协同癌症治疗
Landry et al. Low dose novel PARP-PI3K inhibition via nanoformulation improves colorectal cancer immunoradiotherapy
CN112334127A (zh) 生物响应水凝胶基质及使用方法
US20230390300A1 (en) Neuroblastoma treatment with taurolidine hydrolysis products
KR20060061367A (ko) 디파이브로타이드를 단독으로 또는 다른 항암제들과조합하여 포함하는 항암제제
KR20210054544A (ko) 포유류 체내의 myc-발현 종양에 대한 타우로리딘 치료
US20220323451A1 (en) Taurolidine treatment for myc-expressing tumors in mammalian bodies
CA3008095C (en) A pharmaceutical composition comprising apatite-based matrix and surface modifying agent
KR20210050544A (ko) 타우로리딘 가수분해 생성물을 이용한 신경모세포종 치료
CA2606727A1 (en) Lipid a analogs for treating oral and gastrointestinal mucositis
US20230405132A1 (en) Antitumor pharmaceutical composition and use thereof
US20220323450A1 (en) Methods and compositions for treating neuroblastoma in a juvenile mammalian body
US20160375057A1 (en) Therapeutic compositions and methods involving cell-permeable iron
KR20210050543A (ko) 유년기 포유류 신체내의 신경모세포종을 치료하기 위한 방법 및 조성물
KR20210039414A (ko) 암의 치료를 위한 병용 요법
EP4382134A1 (en) Pharmaceutical composition for preventing or treating triple-negative breast cancer, comprising oligonucleotide as active ingredient
AKTAŞ et al. Neuroblastoma-targeted Anticancer Drug Delivery
WO2008135792A1 (en) Pm00104 compound for use in cancer therapy
WO2016201378A1 (en) Multi-drug combinations that act as potent radiosensitizers
Martin et al. RXDX-107, A Dodecanol Alkyl Ester of Bendamustine, Demonstrates Greater Stability and Broad Antitumor Activity in Multiple Pre-Clinical Models of Solid Tumor
Sadat Nanodelivery of novel inhibitors of DNA repair for enhanced cancer therapy
Rincon-Torroella et al. ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1
Akotiah et al. Drug Targeting and Therapeutic Management of Chronic Myeloid Leukemia: Conventional and Nanotherapeutic Drug Options